SHIM
ORKA

Stone House Investment Management’s Oruka Therapeutics ORKA Stock Holding History

Stone House Investment Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.1K Buy
1,002
+2
+0.2% +$70 0.01% 181
2025
Q4 		$30.3K Hold
1,000
– – ﹤0.01% 211
2025
Q3 		$19.2K Buy
+1,000
New +$14.8K ﹤0.01% 230

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Stone House Investment Management's ORKA Position: Q1 2026 in Review

Stone House Investment Management increased its Oruka Therapeutics (ORKA) stake by 0.2% in Q1 2026, buying an estimated $70 and bringing the position to 1,002 shares worth $49.1K. The position accounts for 0.01% of the portfolio, ranked #181.

Stone House Investment Management first reported a position in ORKA in Q3 2025 and has held it in 3 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Stone House Investment Management held 1,002 shares of Oruka Therapeutics worth $49.1K as of Q1 2026.
  • Stone House Investment Management bought 2 Oruka Therapeutics shares in Q1 2026, an estimated $70.
  • Oruka Therapeutics made up 0.01% of Stone House Investment Management's portfolio in Q1 2026, its #181 holding.
  • Stone House Investment Management first reported a position in Oruka Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.